LB Pharmaceuticals Inc LBRX
40.33 USD +1.29 (+3.30%)
At closeNov 3, 2026, 4:01 PM EST
40.33 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
39.15 Day range 41.40
14.32 52-week range 50.16
- YTD
- +81.18%
- 1 year
- +149.41%
- Market cap
- 1.30B
- EPS (ttm)
- 0.10
- Shares out
- 32.26M
- P/E ratio
- 403.30
- Forward P/E
- -7.50
- YTD return
- +81.18%
- 1-year return
- +149.41%
- Volume
- 245.82K
- Avg volume
- 361.92K
- Open
- 39.65
- Previous close
- 39.04
- Day's range
- 39.15 – 41.40
- 52-week range
- 14.32 – 50.16
- Analysts
- Strong Buy
- Price target
- 58.00 (+43.8%)
- Earnings date
- Nov 5, 2026
2Y +23.05 (+133.24%)
Key statistics
- Enterprise value
- 936.83M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.48
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -53.92M
- Total cash
- 327.79M
- Total debt
- 5.22M
- Return on equity
- -50.00%
- Short % of float
- 20.29%
- 50-day average
- 41.20
- 200-day average
- 32.66
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 58.00 +43.8% upside
Now 40.33
- Target (low)
- 35.00
- Target (mean)
- 58.00
- Target (high)
- 80.00
Ratings (0m) 11 10 buy · 1 hold · 0 sell
- Strong buy2
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -1.60.
Financials — quick view
LBRX Revenue — quarterly 0
LBRX Net income — quarterly -51.60M
LBRX EPS — quarterly -1.71
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -1.62 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.80366 | -1.71 | -0.91 | -112.78% |
| May 12, 2026 | Mar 31, 2026 | -0.75 | -0.67 | +0.08 | +10.67% |
| Mar 26, 2026 | Dec 31, 2025 | -0.45 | -0.45 | 0.00 | 0.00% |
| Nov 6, 2025 | Sep 30, 2025 | -0.57 | -0.61 | -0.04 | -7.02% |
| Sep 8, 2025 | Jun 30, 2025 | — | -1.44 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | Canaccord Genuity | init | — | Buy |
| Oct 6, 2026 | Guggenheim | init | — | Buy |
| Oct 5, 2026 | Roth Capital | down | Buy | Neutral |
| Oct 2, 2026 | Needham | init | — | Buy |
| Aug 24, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 12, 2026 | BMO Capital | main | Outperform | Outperform |
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lbpharma.us
News
LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia 
LB Pharmaceuticals to Participate in Upcoming Investor Events 
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday 
Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65 
Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80 
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment - Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Needham Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $68
LB Pharmaceuticals Inc (NASDAQ:LBRX) Stock Has Average Target Price of $49.62
Your note
Sign in to keep a note on LBRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DEEP TRACK BIOTECHNOLOGY MASTER FUND LTD | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 11, 2025 | 0 |
| NUSSBAUM RAN | Director | Conversion of Exercise of derivative security | Sep 11, 2025 | 0 |
| PONTIFAX MANAGEMENT 4 G.P. 2015, LTD. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 11, 2025 | 0 |
| VIDA VENTURES GP III, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 11, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deep Track Capital, Lp | 10.39% | 3,352,804 | 135.22M | Jun 29, 2026 |
| Blackrock Inc. | 8.48% | 2,734,305 | 110.27M | Jun 29, 2026 |
| RA Capital Management, L.P. | 6.85% | 2,208,604 | 89.07M | Jun 29, 2026 |
| Trails Edge Capital Partners, LP | 4.72% | 1,523,022 | 61.42M | Jun 29, 2026 |
| Commodore Capital Lp | 4.65% | 1,500,000 | 60.50M | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 4.64% | 1,497,293 | 60.39M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 2.15% | 692,905 | 27.94M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.08% | 672,000 | 27.10M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.80% | 581,677 | 23.46M | Sep 29, 2026 |
| BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 1.76% | 567,627 | 22.89M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.86% | 278,887 | 11.25M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.76% | 245,436 | 9.90M | Aug 30, 2026 |